The cost regulator for the U.K.'s publicly-funded National Health Service has reversed its earlier stance on U.S.-based Allergan Inc.'s (AGN) wrinkle-fighting drug Botox and now recommends its use for some patients suffering from migraine headaches. The independent National Institute for Health and Clinical Excellence Friday said in final draft guidance that its advisory committee now recommends use of the injected medicine, known chemically as botulinum toxin type A, for some adult patients with chronic migraine, after NICE received more information on the product from the company. The body had previously said it was not convinced of the value of funding the therapy on the NHS.